Efficacy and safety of Cheonwangbosim-dan (Tian Wang Bu Xin Dan) for treatment of mild cognitive impairment: A randomized placebo-controlled pilot trial.
Mild cognitive impairment (MCI), an intermediate condition between healthy cognitive changes due to aging and dementia, is a risk factor for dementia. Cheonwangbosim-dan (CWBSD) is a traditional herbal medicine widely used to improve mental and physical illness in East Asia. We aimed to investigate...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0326227 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850102680333058048 |
|---|---|
| author | Jae-Hong Kim Ae-Ran Kim Bok-Nam Seo Gwang-Cheon Park Jeong-Soon Lee |
| author_facet | Jae-Hong Kim Ae-Ran Kim Bok-Nam Seo Gwang-Cheon Park Jeong-Soon Lee |
| author_sort | Jae-Hong Kim |
| collection | DOAJ |
| description | Mild cognitive impairment (MCI), an intermediate condition between healthy cognitive changes due to aging and dementia, is a risk factor for dementia. Cheonwangbosim-dan (CWBSD) is a traditional herbal medicine widely used to improve mental and physical illness in East Asia. We aimed to investigate the safety and efficacy of CWBSD in the treatment of MCI. This clinical trial adopted a double-blind, single-center, parallel-arm, prospective, randomized controlled pilot study design with a full analysis set. Forty-eight participants with MCI were randomized to the control or CWBSD groups. The participants were administered either placebo or CWBSD once daily (at a dose of 3 g) for twenty-four weeks. The primary outcome measure was a change in the Korean version of the Montreal Cognitive Assessment Scale (MoCA-K). The secondary outcome measures included memory, quality of life, depression, and level of activity in daily living. Safety measures were conducted by comparing the occurrence of adverse events and changes in blood chemistry parameters, pulse rate, and blood pressure between the two groups. After 24 weeks of treatment, no significant differences in the changes in the total MoCA-K scores were detected between the two groups. Changes in secondary outcomes were not significantly different between the two groups. In the safety evaluation, there was no significant difference between the two groups with regard to the occurrence of adverse events and changes in blood chemistry parameters, blood pressure, and pulse rate. We demonstrated that CWBSD treatment may be safe and does not significantly improve cognitive function, quality of life, daily activities, or depression in individuals with MCI. Further studies are necessary to validate the efficacy and safety of CWBSD in the treatment of MCI. Trial registration Clinical Research Information Service KCT0006787. |
| format | Article |
| id | doaj-art-b10c8e1bca624a1ebe2dacc3b409d852 |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-b10c8e1bca624a1ebe2dacc3b409d8522025-08-20T02:39:41ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01207e032622710.1371/journal.pone.0326227Efficacy and safety of Cheonwangbosim-dan (Tian Wang Bu Xin Dan) for treatment of mild cognitive impairment: A randomized placebo-controlled pilot trial.Jae-Hong KimAe-Ran KimBok-Nam SeoGwang-Cheon ParkJeong-Soon LeeMild cognitive impairment (MCI), an intermediate condition between healthy cognitive changes due to aging and dementia, is a risk factor for dementia. Cheonwangbosim-dan (CWBSD) is a traditional herbal medicine widely used to improve mental and physical illness in East Asia. We aimed to investigate the safety and efficacy of CWBSD in the treatment of MCI. This clinical trial adopted a double-blind, single-center, parallel-arm, prospective, randomized controlled pilot study design with a full analysis set. Forty-eight participants with MCI were randomized to the control or CWBSD groups. The participants were administered either placebo or CWBSD once daily (at a dose of 3 g) for twenty-four weeks. The primary outcome measure was a change in the Korean version of the Montreal Cognitive Assessment Scale (MoCA-K). The secondary outcome measures included memory, quality of life, depression, and level of activity in daily living. Safety measures were conducted by comparing the occurrence of adverse events and changes in blood chemistry parameters, pulse rate, and blood pressure between the two groups. After 24 weeks of treatment, no significant differences in the changes in the total MoCA-K scores were detected between the two groups. Changes in secondary outcomes were not significantly different between the two groups. In the safety evaluation, there was no significant difference between the two groups with regard to the occurrence of adverse events and changes in blood chemistry parameters, blood pressure, and pulse rate. We demonstrated that CWBSD treatment may be safe and does not significantly improve cognitive function, quality of life, daily activities, or depression in individuals with MCI. Further studies are necessary to validate the efficacy and safety of CWBSD in the treatment of MCI. Trial registration Clinical Research Information Service KCT0006787.https://doi.org/10.1371/journal.pone.0326227 |
| spellingShingle | Jae-Hong Kim Ae-Ran Kim Bok-Nam Seo Gwang-Cheon Park Jeong-Soon Lee Efficacy and safety of Cheonwangbosim-dan (Tian Wang Bu Xin Dan) for treatment of mild cognitive impairment: A randomized placebo-controlled pilot trial. PLoS ONE |
| title | Efficacy and safety of Cheonwangbosim-dan (Tian Wang Bu Xin Dan) for treatment of mild cognitive impairment: A randomized placebo-controlled pilot trial. |
| title_full | Efficacy and safety of Cheonwangbosim-dan (Tian Wang Bu Xin Dan) for treatment of mild cognitive impairment: A randomized placebo-controlled pilot trial. |
| title_fullStr | Efficacy and safety of Cheonwangbosim-dan (Tian Wang Bu Xin Dan) for treatment of mild cognitive impairment: A randomized placebo-controlled pilot trial. |
| title_full_unstemmed | Efficacy and safety of Cheonwangbosim-dan (Tian Wang Bu Xin Dan) for treatment of mild cognitive impairment: A randomized placebo-controlled pilot trial. |
| title_short | Efficacy and safety of Cheonwangbosim-dan (Tian Wang Bu Xin Dan) for treatment of mild cognitive impairment: A randomized placebo-controlled pilot trial. |
| title_sort | efficacy and safety of cheonwangbosim dan tian wang bu xin dan for treatment of mild cognitive impairment a randomized placebo controlled pilot trial |
| url | https://doi.org/10.1371/journal.pone.0326227 |
| work_keys_str_mv | AT jaehongkim efficacyandsafetyofcheonwangbosimdantianwangbuxindanfortreatmentofmildcognitiveimpairmentarandomizedplacebocontrolledpilottrial AT aerankim efficacyandsafetyofcheonwangbosimdantianwangbuxindanfortreatmentofmildcognitiveimpairmentarandomizedplacebocontrolledpilottrial AT boknamseo efficacyandsafetyofcheonwangbosimdantianwangbuxindanfortreatmentofmildcognitiveimpairmentarandomizedplacebocontrolledpilottrial AT gwangcheonpark efficacyandsafetyofcheonwangbosimdantianwangbuxindanfortreatmentofmildcognitiveimpairmentarandomizedplacebocontrolledpilottrial AT jeongsoonlee efficacyandsafetyofcheonwangbosimdantianwangbuxindanfortreatmentofmildcognitiveimpairmentarandomizedplacebocontrolledpilottrial |